How are TGTX strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the TGTX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 44.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$295.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a TGTX strangle?

The breakeven for the TGTX strangle priced on this page is roughly $35.05 and $43.95 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TGTX market-implied 1-standard-deviation expected move is approximately 12.61%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current TGTX implied volatility affect this strangle?

TGTX ATM IV is at 44.00% with IV rank near 5.52%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

TGTX Strangle Strategy

TGTX (TG Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A.

TGTX (TG Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $6.53B, a trailing P/E of 13.34, a beta of 1.68 versus the broader market, a 52-week range of 25.28-44.65, average daily share volume of 2.1M, a public-listing history dating back to 2010, approximately 352 full-time employees. These structural characteristics shape how TGTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.68 indicates TGTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on TGTX?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current TGTX snapshot

As of May 15, 2026, spot at $39.50, ATM IV 44.00%, IV rank 5.52%, expected move 12.61%. The strangle on TGTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on TGTX specifically: TGTX IV at 44.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a TGTX strangle, with a market-implied 1-standard-deviation move of approximately 12.61% (roughly $4.98 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TGTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on TGTX should anchor to the underlying notional of $39.50 per share and to the trader's directional view on TGTX stock.

TGTX strangle setup

The TGTX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TGTX near $39.50, the first option leg uses a $41.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TGTX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TGTX shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$41.00	$1.68
Buy 1	Put	$38.00	$1.28

TGTX strangle risk and reward

Net Premium / Debit: -$295.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$295.00
Breakeven(s): $35.05, $43.95
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

TGTX strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on TGTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$3,504.00
$8.74	-77.9%	+$2,630.74
$17.48	-55.8%	+$1,757.49
$26.21	-33.7%	+$884.23
$34.94	-11.5%	+$10.97
$43.67	+10.6%	-$27.72
$52.41	+32.7%	+$845.54
$61.14	+54.8%	+$1,718.79
$69.87	+76.9%	+$2,592.05
$78.60	+99.0%	+$3,465.31

When traders use strangle on TGTX

Strangles on TGTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TGTX chain.

TGTX thesis for this strangle

The market-implied 1-standard-deviation range for TGTX extends from approximately $34.52 on the downside to $44.48 on the upside. A TGTX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current TGTX IV rank near 5.52% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on TGTX at 44.00%. As a Healthcare name, TGTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TGTX-specific events.

TGTX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TGTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TGTX alongside the broader basket even when TGTX-specific fundamentals are unchanged. Always rebuild the position from current TGTX chain quotes before placing a trade.

Frequently asked questions

What is a strangle on TGTX?: A strangle on TGTX is the strangle strategy applied to TGTX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With TGTX stock trading near $39.50, the strikes shown on this page are snapped to the nearest listed TGTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are TGTX strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the TGTX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 44.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$295.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a TGTX strangle?: The breakeven for the TGTX strangle priced on this page is roughly $35.05 and $43.95 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TGTX market-implied 1-standard-deviation expected move is approximately 12.61%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on TGTX?: Strangles on TGTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TGTX chain.
How does current TGTX implied volatility affect this strangle?: TGTX ATM IV is at 44.00% with IV rank near 5.52%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.